After propensity-score matching, the two cohorts (241 in each cohort, mean age 51.8 years, 39.0% women, 32.6% black, 44.4% white, 5.8% Hispanic) were balanced (see Supplementary Table S3 in the Supplementary Appendix)
While these studies suggest potential benefits, they do not provide the level of evidence needed to confirm safety and efficacy in humans
Stay consistent with movement Exercise enhances fat loss and helps maintain muscle
Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release
Patients with genetic variants associated with GLP-1 receptor hypersensitivity may achieve excellent results at the 0.25mg dose, while those with reduced receptor sensitivity might need earlier advancement to higher doses
Measurable weight loss typically begins within two to four weeks